Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with a primary emphasis on breast cancer. The company’s current pipeline centers on palazestrant (OP-1250), an oral estrogen receptor antagonist and selective estrogen receptor degrader being studied for hormone receptor-positive breast cancer, and OP-3136, a KAT6 inhibitor in early clinical development. Olema’s research is built around endocrine-driven cancers and mechanisms of acquired resistance, reflecting a focus on precision oncology approaches for difficult-to-treat disease settings. The company is headquartered in San Francisco, California, with additional operations in Cambridge, Massachusetts. Olema Pharmaceuticals, Inc. plays a specialized role in the biotechnology market as a development-stage oncology company advancing novel medicines for breast cancer and related women’s cancers.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Sean P. Bohen M.D., Ph.D.

Employees

150

Headquarters

San Francisco, CA, United States

Website

olema.com